TCT 28: Predictors of procedural success and LV remodeling following transcatheter and surgical mitral valve repair and replacement – a post-hoc analysis of the MATTERHORN trial

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Abbott; Edwards Lifesciences</li></ul>